Authors:
Schuijt, MP
Basdew, M
Van Veghel, R
De Vries, R
Saxena, PR
Schoemaker, RG
Danser, AHJ
Citation: Mp. Schuijt et al., AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction, AM J P-HEAR, 281(6), 2001, pp. H2590-H2596
Authors:
Lankhuizen, IM
van Veghel, R
Saxena, PR
Schoemaker, RG
Citation: Im. Lankhuizen et al., Vascular and renal effects of vasopressin and its antagonists in consciousrats with chronic myocardial infarction; evidence for receptor shift, EUR J PHARM, 423(2-3), 2001, pp. 195-202
Authors:
Lankhuizen, IM
van Veghel, R
Saxena, PR
Schoemaker, RG
Citation: Im. Lankhuizen et al., [Arg(8)]-vasopressin-induced responses on coronary and mesenteric arteriesof rats with myocardial infarction: The effects of V-1a- and V-2-receptor antagonists, J CARDIO PH, 36(1), 2000, pp. 38-44
Authors:
de Jong, JW
Schoemaker, RG
de Jonge, R
Bernocchi, P
Keijzer, E
Harrison, R
Sharma, HS
Ceconi, C
Citation: Jw. De Jong et al., Enhanced expression and activity of xanthine oxidoreductase in the failingheart, J MOL CEL C, 32(11), 2000, pp. 2083-2089
Authors:
Van Kerckhoven, R
van Veen, TAB
Boomsma, F
Saxena, PR
Schoemaker, RG
Citation: R. Van Kerckhoven et al., Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model, EUR J PHARM, 397(1), 2000, pp. 113-120
Authors:
Van Kerckhoven, R
Kalkman, EAJ
Saxena, PR
Schoemaker, RG
Citation: R. Van Kerckhoven et al., Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts, CARDIO RES, 46(2), 2000, pp. 316-323
Authors:
Fechner, H
Haack, A
Wang, H
Wang, X
Eizema, K
Pauschinger, M
Schoemaker, RG
van Veghel, R
Houtsmuller, AB
Schultheiss, HP
Lamers, JMJ
Poller, W
Citation: H. Fechner et al., Expression of Coxsackie adenovirus receptor and alpha(v)-integrin does notcorrelate with adenovector targeting in vivo indicating anatomical vector barriers, GENE THER, 6(9), 1999, pp. 1520-1535
Authors:
Kalkman, EAJ
van Haren, P
Saxena, PR
Schoemaker, RG
Citation: Eaj. Kalkman et al., Early captopril prevents myocardial infarction-induced hypertrophy but notangiogenesis, EUR J PHARM, 369(3), 1999, pp. 339-348